companyNewsغير مصنف

Amgen’s multiple myeloma drug falls short in late stage study

Sept 27 (Reuters) – Amgen Inc said on Tuesday its
cancer drug Kyprolis failed to meet the main goal of a
late-stage study against Takeda Pharmaceutical Co Ltd’s
Velcade for treating newly diagnosed multiple myeloma.

اظهر المزيد

مقالات ذات صلة

زر الذهاب إلى الأعلى